Saxenda Cost in Texas (2026): Prices, Insurance, and Savings Options

Saxenda Retail Pricing in Texas

The manufacturer list price for Saxenda from Novo Nordisk is $1,349 per month in 2026, covering a five-pen carton that supplies 30 days at the maintenance dose of 3 mg daily. This price holds across most Texas retail pharmacies, from CVS and Walgreens locations in Houston to independent pharmacies in El Paso and Lubbock.

Price variation between Texas pharmacies is minimal for brand-name Saxenda because Novo Nordisk sets a uniform wholesale acquisition cost. Some pharmacies may offer slightly different dispensing fees, but the difference rarely exceeds $20 to $30 per fill. Discount platforms such as GoodRx, RxSaver, and SingleCare sometimes list Saxenda between $1,100 and $1,300 at select Texas locations, though availability fluctuates.

Saxenda was FDA-approved in December 2014 for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. In the SCALE Obesity and Prediabetes trial (N=3,731), participants on liraglutide 3 mg lost a mean of 8.0% body weight at 56 weeks compared to 2.6% with placebo [1]. The 56-week completion rate was 72% in the liraglutide group. These efficacy data drive much of the demand across Texas, where the adult obesity rate exceeds 36% according to CDC data [2].

Without insurance or discount programs, a full year of Saxenda therapy costs approximately $16,188. That figure does not account for the dose-escalation period during weeks one through four, when patients use less medication daily.

Texas Medicaid and Saxenda

Texas Medicaid does not cover Saxenda for chronic weight management. Coverage extends only to liraglutide at lower doses (0.6 mg to 1.8 mg daily under the brand name Victoza) for the treatment of type 2 diabetes.

This exclusion reflects a broader pattern: most state Medicaid programs classify anti-obesity medications as "optional" rather than mandatory benefits. The Endocrine Society's 2015 clinical practice guideline recommends pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with comorbidities, but Medicaid formulary committees in Texas have not adopted this recommendation for liraglutide 3 mg coverage [3].

Texas Health and Human Services does cover bariatric surgery under limited conditions for Medicaid recipients, which creates an inconsistency. A Roux-en-Y gastric bypass costs $20,000 to $35,000 per procedure, while a year of Saxenda costs roughly $16,188 at list price. Patients enrolled in Texas Medicaid who need obesity pharmacotherapy may need to explore manufacturer assistance programs or compounded alternatives.

For Texans on Medicaid managed care plans (such as those administered by Molina, Superior, or Amerigroup), the formulary exclusion applies uniformly. Appeals are possible but rarely successful for weight-management indications.

Commercial Insurance Coverage in Texas

Several major commercial insurers in Texas cover Saxenda, though coverage almost always requires prior authorization and documentation of medical necessity. Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, and Cigna each maintain formulary listings for Saxenda with varying tier placements and cost-sharing structures.

Typical prior authorization requirements include: documented BMI ≥30 (or ≥27 with a comorbidity), a record of failed dietary and exercise interventions for at least three to six months, and sometimes prior trial of a lower-cost obesity medication such as phentermine. Some plans require step therapy, meaning the prescriber must show that the patient tried and failed a first-line agent before Saxenda is authorized.

When covered, copays for Saxenda on a preferred specialty tier range from $50 to $150 per month. Non-preferred placement can push copays above $200 per month or apply coinsurance of 25% to 40% after the deductible is met.

The American Association of Clinical Endocrinology (AACE) 2024 obesity algorithm classifies liraglutide 3 mg as a first- or second-line pharmacotherapy option depending on BMI stage and complication burden [4]. Citing this guideline in prior authorization letters can strengthen approval likelihood.

Employer-sponsored plans in Texas, especially those from large employers in the Dallas-Fort Worth, Houston, and Austin metro areas, are more likely to include obesity medication coverage than small-group plans. Self-funded employer plans have the flexibility to add anti-obesity medication benefits without state insurance mandate constraints, and an increasing number are doing so as obesity-related healthcare costs continue to rise.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Saxenda that reduces the out-of-pocket cost to as low as $25 per month for eligible patients. Eligibility requires commercial insurance coverage for Saxenda. Patients with government insurance (Medicare, Medicaid, TRICARE, VA benefits) do not qualify.

The savings card covers up to $200 off each 30-day prescription fill for a maximum of 12 months, after which the patient must re-enroll. Enrollment is available online through the Saxenda website or by phone. Texas patients using the card at participating pharmacies (which include most major chains) can combine it with their commercial copay to reduce total out-of-pocket spending.

For uninsured patients, Novo Nordisk also operates the Patient Assistance Program (PAP), which provides Saxenda at no cost to qualifying individuals. Income thresholds typically fall at or below 400% of the federal poverty level, and applicants must have no prescription drug coverage. Processing takes two to four weeks, and approved patients receive a 90-day supply shipped directly or via a designated pharmacy.

According to Novo Nordisk's prescribing information, Saxenda should be discontinued if a patient has not lost at least 4% of baseline body weight by 16 weeks at the full 3 mg dose [5]. This stopping rule limits exposure to costs when the medication is not producing adequate results.

Compounded Liraglutide 3 mg in Texas

Compounded liraglutide 3 mg is available in Texas through licensed 503A compounding pharmacies. The Texas State Board of Pharmacy regulates these facilities, and they must compound pursuant to valid patient-specific prescriptions from licensed prescribers.

Compounded liraglutide offers a significant cost reduction. Prices vary by pharmacy but typically range from $200 to $500 per month, a fraction of the brand-name $1,349. Some Texas-based compounding pharmacies advertise monthly costs under $300 for liraglutide 3 mg formulations.

A few points to consider. Compounded medications are not FDA-approved products. They do not undergo the same manufacturing, testing, and quality-assurance processes as commercially manufactured drugs. The FDA's guidance on compounding distinguishes between 503A pharmacies (patient-specific prescriptions) and 503B outsourcing facilities (which can produce larger batches under stricter FDA oversight) [6].

In Texas, the legality of compounded liraglutide rests on whether the prescriber writes a valid prescription and the pharmacy holds a current Texas State Board of Pharmacy license. Liraglutide is not on the FDA's "do not compound" list as of mid-2025, so 503A pharmacies may compound it. Patients should verify that their compounding pharmacy is licensed by the Texas board and ask about third-party potency testing.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "Compounded GLP-1 receptor agonists can be a reasonable option when cost is a barrier, but patients need to ensure they are working with a reputable pharmacy that tests its products for potency and sterility" [7].

Telehealth Access to Saxenda in Texas

Texas law permits telehealth prescribing of Saxenda. The Texas Medical Board allows physicians and advanced practice providers to establish a patient-provider relationship via synchronous audio-video encounter and prescribe controlled and non-controlled medications, including Saxenda, without an in-person visit.

Multiple telehealth platforms now serve Texas patients seeking Saxenda prescriptions. These platforms typically charge a consultation fee of $50 to $200, with some including follow-up visits in a monthly membership model. The prescription is then sent to a retail or compounding pharmacy of the patient's choice.

Telehealth visits for Saxenda in Texas generally include a medical history review, BMI assessment, discussion of weight-loss goals, and screening for contraindications. Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as stated in the FDA boxed warning [5]. Responsible telehealth providers screen for these conditions before prescribing.

The SCALE Maintenance trial showed that patients who continued liraglutide 3 mg after an initial low-calorie diet run-in period lost an additional 6.2% body weight over 56 weeks compared to 0.2% regain with placebo [8]. This weight maintenance benefit underscores the importance of ongoing access, which telehealth facilitates by removing geographic barriers for patients in rural Texas communities.

Cost Comparison: Saxenda vs. Other GLP-1 Options in Texas

Saxenda's $1,349 monthly price positions it between older generic options and newer, more expensive GLP-1 receptor agonists. Here is how it compares for Texas patients:

Phentermine, an older appetite suppressant, costs $15 to $40 per month at Texas pharmacies. It is approved only for short-term use (up to 12 weeks) and works through a different mechanism than GLP-1 receptor agonists.

Wegovy (semaglutide 2.4 mg weekly injection) lists at approximately $1,349 per month as well, but weekly dosing may improve adherence over Saxenda's daily injection schedule. The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo [9]. Saxenda's SCALE trial showed 8.0% mean weight loss at 56 weeks [1]. The difference in efficacy is clinically meaningful.

Zepbound (tirzepatide for weight management) lists between $1,059 and $1,200 per month depending on dose. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and the SURMOUNT-1 trial (N=2,539) reported up to 22.5% mean weight loss at the highest dose over 72 weeks [10].

For Texas patients making a cost-based decision, compounded liraglutide offers the lowest price point for a GLP-1 receptor agonist. Brand Saxenda and Wegovy share similar list prices but differ in efficacy and injection frequency. Zepbound offers the greatest weight loss in trials but is also subject to prior authorization barriers.

How to Reduce Your Saxenda Costs in Texas

Several strategies can lower the effective price of Saxenda for Texas residents.

First, check whether your commercial insurance covers Saxenda by calling the number on your insurance card and asking about the formulary status for liraglutide 3 mg (NDC 0169-4060-12). If covered, ask about tier placement and prior authorization requirements.

Second, enroll in the Novo Nordisk savings card before filling your prescription. The card works at most Texas pharmacies and can reduce copays by up to $200 per fill. Have the pharmacist apply it at the point of sale.

Third, if you are uninsured and your household income falls below 400% of the federal poverty level, apply to the Novo Nordisk Patient Assistance Program. Processing takes two to four weeks, and approval grants free medication for a defined period.

Fourth, discuss compounded liraglutide with your prescriber. If cost is the primary barrier and you cannot obtain insurance coverage or manufacturer assistance, a licensed Texas 503A compounding pharmacy may provide liraglutide 3 mg at a substantially lower price.

Fifth, use the 16-week stopping rule to your advantage. Per FDA labeling, if you have not lost at least 4% of your starting weight after 16 weeks on the full 3 mg dose, discontinue Saxenda and discuss alternatives with your provider [5]. This prevents months of spending on a medication that is not producing results for your body.

The Obesity Medicine Association's 2024 position statement emphasizes that anti-obesity medications should be continued long-term when effective, as weight regain after discontinuation is common [11]. Budget accordingly if Saxenda works for you: this is not a short-course medication.